

**Bio:**

**David Rubinsztein** is Professor of Molecular Neurogenetics and a UK Dementia Research Institute Professor at the University of Cambridge. He is Deputy Director of the Cambridge Institute for Medical Research. Dr. Rubinsztein earned his MB ChB, BSc (Med), and PhD degrees from University of Cape Town. He came to Cambridge in 1993 as a Senior Registrar in genetic pathology. His research is focused in the field of autophagy, particularly in the context of neurodegenerative diseases. He has held Glaxo Wellcome, and Wellcome Senior and Principal Fellowships and currently is a UK Dementia Research Institute Group Leader. His laboratory pioneered the strategy of autophagy upregulation as a possible therapeutic approach in various neurodegenerative diseases and has identified drugs and novel pathways that may be exploited for this objective. He has made contributions that reveal the relevance of autophagy defects as a disease mechanism and to the basic cell biology of this important catabolic process. Rubinsztein was elected Fellow of the Academy of Medical Sciences (2004), EMBO member (2011) and Fellow of the Royal Society (2017). He was awarded the Graham Bull Prize (2007), Thudichum Medal (2017), Roger de Spoelberch prize (2017) and the Goudie Medal (2020). He was identified as a Clarivates Analytics Highly Cited Researcher (2018, 2019, 2020).

**Terms of Appointment**

Jan 2021 - Jan 2025